Filing Details

Accession Number:
0001209191-21-017543
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-03 20:39:03
Reporting Period:
2021-03-01
Accepted Time:
2021-03-03 20:39:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1340652 Chemocentryx Inc. CCXI Pharmaceutical Preparations (2834) 943254365
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1422995 J. Markus Cappel C/O Chemocentryx, Inc.
850 Maude Avenue
Mountain View CA 94043
Chief Bus. Officer & Treasurer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-03-01 5,417 $6.62 91,243 No 4 M Direct
Common Stock Acquisiton 2021-03-01 11,667 $10.86 102,910 No 4 M Direct
Common Stock Acquisiton 2021-03-01 16,008 $11.02 118,918 No 4 M Direct
Common Stock Disposition 2021-03-01 7,053 $67.68 111,865 No 4 S Direct
Common Stock Disposition 2021-03-01 20,680 $68.51 91,185 No 4 S Direct
Common Stock Disposition 2021-03-01 5,359 $69.09 85,826 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2021-03-01 5,417 $0.00 5,417 $6.62
Common Stock Stock Option (right to buy) Disposition 2021-03-01 11,667 $0.00 11,667 $10.86
Common Stock Stock Option (right to buy) Disposition 2021-03-01 16,008 $0.00 16,008 $11.02
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
18,958 2027-02-28 No 4 M Direct
24,792 2028-03-05 No 4 M Direct
42,292 2029-03-04 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  2. Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $66.99 to $67.98 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
  3. Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $68.00 to $68.98 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
  4. Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $69.00 to $69.24 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
  5. As of March 1, 2021, and prior to this transaction, the exercised options were fully vested.
  6. Not applicable.